Veeva (VEEV) Q2 2027 Earnings Call Transcript

Veeva Systems reported Q2 FY2027 total revenue of $928.0M (+18% YoY) and non-GAAP operating income of $415.9M (44.8% margin), with subscription revenue up 16% YoY to $766.8M. The company raised FY2027 revenue guidance to $3,682M–$3,687M and FY2027 non-GAAP EPS guidance to ~ $9.21, while also updating Q3 revenue guidance to $932M–$935M. Veeva accelerated AI platform commercialization (Veeva Falcon) and spent $472.7M on share repurchases in the first six months, reinforcing confidence in profitability and demand (over 180 Vault CRM customers; multiple top-20 biopharma commitments).

Analysis

The key market implication is not simply “strong quarter,” but that Veeva is converting AI from a threat to a moat. If Falcon works, the company stops being a pure software vendor and starts monetizing workflow labor inside the same buyer relationship, which should expand wallet share and raise switching costs for CRM/R&D incumbents; that is structurally negative for point-solution vendors and for broad horizontal suites that lack domain depth, especially CRM. The near-term beneficiary is VEEV itself; secondary beneficiaries are specialist implementation/service partners that can attach to a more complex product stack, while generic consulting/outsourcing models face margin pressure as customers demand faster, tech-enabled deployments.

The catalyst path is staged. Over the next 1-3 months, the important checks are whether the remaining top-tier CRM decisions close and whether the first Falcon go-lives validate the “faster time-to-value” story. Over 6-18 months, the bigger question is monetization: if AI features are priced like labor but delivered with software-like gross margins, VEEV’s multiple can stay premium; if model costs rise faster than deterministic automation, the market will haircut the AI narrative. Falsifiers are delayed Falcon launches, any evidence that CRM win-backs are slipping into 2028+, or margin compression from early AI delivery costs.

Contrarian view: the street may be underestimating how much customers prefer buying AI from an incumbent platform with compliance credibility, not a startup, and overestimating the risk that AI commoditizes Veeva. The bigger overhang is execution, not demand. Aspen is the softer part of the story: attractive strategically, but too early to underwrite as meaningful revenue, so it should not be the basis for a near-term re-rating by itself.

Key Decisions for Investors

• Add to VEEV on any post-earnings pullback; use a 1-3 month horizon and focus on the remaining top-20 CRM decisions plus first Falcon go-lives as the next upside catalyst.
• Relative value: long VEEV / short CRM to express vertical CRM share capture and execution gap; thesis breaks if Salesforce ramps large-life-sciences conversions cleanly over the next two quarters.
• Buy a 6-12 month VEEV call spread rather than outright equity if valuation is already rich; downside is capped if Falcon/Aspen remain early, upside comes from AI-driven multiple durability.
• Watch IQV as a secondary beneficiary of deeper Veeva-IQVIA collaboration in data/services; consider long IQV only on evidence that the partnership is driving incremental pipeline rather than just relationship optics.
• Set a risk alert on VEEV gross margin and FY27 guide into the next update; any AI-related margin slippage or deferred Falcon monetization would be the first sign the market is overpaying for the story.